Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Oncolys Plans to Begin Japan PII Study of Oncolytic Virus in 2nd Half of 2019
Oncolys BioPharma plans to initiate a PII study of its oncolytic virus telomelysin in Japan in the second half of 2019 to obtain data for regulatory approval for an indication of esophageal cancer, President Yasuo Urata told Jiho, indicating its…
To read the full story
Related Article
- Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
May 21, 2019
- Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
- Oncolys in Talks with Checkpoint Drug Makers for Telomelysin: President
February 12, 2019
- Investigator-Initiated US PII Study to Start for Telomelysin/Keytruda Combo: Oncolys
January 9, 2019
- Oncolys Initiates Company-Sponsored PI Trial of Oncolytic Virus for Treatment of Esophageal Cancer
July 11, 2017
BUSINESS
- PMP Returns Slam Drug Makers' Leading Products, Prazaxa Cut 45%: Jiho Poll
March 13, 2026
- Lilly to Invest Additional 20 Billion Yen in Japan's Seishin Plant
March 13, 2026
- Fujifilm Invests in Austria’s Valanx Biotech to Boost ADC Technology
March 13, 2026
- Merck, CDMO Cyto-Facto Join Hands on Cell and Gene Therapy
March 13, 2026
- Anti-PD-1 Agonist Antibody Enters PI in Australia for Autoimmune Diseases: Meiji
March 13, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…